Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Drug Profile

Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Alternative Names: RX 01413; RX 01423; RX 01445; RX-01; RX-01(a); RX-01(b); RX-01_413; RX-01_423; RX-01_445; RX-02; RX-03; RX-04; RX-05; RX-P770; RX-P873

Latest Information Update: 15 Sep 2014

Price : $50

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics
  • Class Macrolides; Oxadiazoles; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 08 Sep 2014 Preclinical antimicrobial data in Bacterial infections presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2014)
  • 07 Oct 2013 Rib-X Pharmaceuticals is now called Melinta Therapeutics
  • 10 Oct 2012 RX 02 research programme is available for licensing as of 10 Oct 2012. www.rib-x.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top